Band ratio measures, computed as the ratio of power between two frequency bands, are a common analysis measure in neuroelectrophysiological recordings. Band ratio measures are typically interpreted as reflecting quantitative measures of periodic, or oscillatory, activity. This assumes that the measure reflects relative powers of distinct periodic components that are well captured by predefined frequency ranges. However, electrophysiological signals contain periodic components and a 1/f-like aperiodic component, the latter of which contributes power across all frequencies. Here, we investigate whether band ratio measures truly reflect oscillatory power differences, and/or to what extent ratios may instead reflect other periodic changes, such as in center frequency or bandwidth, and/or aperiodic activity. In simulation, we investigate how band ratio measures relate to changes in multiple spectral features, and show how multiple periodic and aperiodic features influence band ratio measures. We validate these findings in human electroencephalography (EEG) data, comparing band ratio measures to parameterizations of power spectral features and find that multiple disparate features influence ratio measures. For example, the commonly applied θ/β ratio is most reflective of differences in aperiodic activity, and not oscillatory θ or β power. Collectively, we show that periodic and aperiodic features can create the same observed changes in band ratio measures, and that this is inconsistent with their typical interpretations as measures of periodic power. We conclude that band ratio measures are a non-specific measure, conflating multiple possible underlying spectral changes, and recommend explicit parameterization of neural power spectra as a more specific approach.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768281 | PMC |
http://dx.doi.org/10.1523/ENEURO.0192-20.2020 | DOI Listing |
Trials
January 2025
London Centre for Primary Care, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Background: The aim of the SURECAN trial is to evaluate a person-centred intervention, based on Acceptance and Commitment Therapy (ACT Plus ( +)), for people who have completed treatment for cancer with curative intent, but are experiencing poor quality of life. We present the statistical analysis plan for assessing the effectiveness and cost-effectiveness of the intervention in improving quality of life 1 year post randomisation.
Methods And Design: SURECAN is a multi-centre, pragmatic, two-arm, partially clustered randomised controlled superiority trial comparing the effectiveness of ACT + added to usual care with usual aftercare.
BMC Palliat Care
January 2025
Palliative Care Unit, National Cancer Institute, Rio de Janeiro, Brazil.
Objective: To compare the sociodemographic and clinical profiles of patients with advanced cancer admitted to a tertiary palliative care unit before and during the COVID-19 pandemic.
Methods: This is an analysis of data from patients receiving care before (10/21/2019 to 03/16/2020) and during (09/23/2020 to 08/26/2021) the COVID-19 pandemic. Sociodemographic and clinical data were evaluated.
BMC Med Imaging
January 2025
Department of Radiology, Huadong Hospital, Fudan University, Shanghai, 200040, China.
Background: Interstitial lung abnormalities (ILA) are a proposed imaging concept. Fibrous ILA have a higher risk of progression and death. Clinically, computed tomography (CT) examination is a frequently used and convenient method compared with pulmonary function tests.
View Article and Find Full Text PDFJ Gen Intern Med
January 2025
Executive Division, National Center for PTSD, White River Junction, USA.
Background: Moral injury affects a variety of populations who make ethically complex decisions involving their own and others' well-being, including combat veterans, healthcare workers, and first responders. Yet little is known about occupational differences in the prevalence of morally injurious exposures and outcomes in nationally representative samples of such populations.
Objective: To examine prevalence of potentially morally injurious event (PMIE) exposure and clinically meaningful moral injury in three high-risk groups.
Biochem Genet
January 2025
Department of Physiology, University of Louisville School of Medicine, Louisville, KY, 40202, USA.
Although DNA methyltransferase 1 (DNMT1) and RNA editor ADAR triplications exist in Down syndrome (DS), their specific roles remain unclear. DNMT methylates DNA, yielding S-adenosine homocysteine (SAH), subsequently converted to homocysteine (Hcy) and adenosine by S-adenosine homocysteine (Hcy) hydrolase (SAHH). ADAR converts adenosine to inosine and uric acid.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!